Navigation Links
Medicines from plants
Date:5/26/2011

This release is available in German.

Medicines from plants one thinks of herbal teas or valerian drops. However, that has nothing in common with what the researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in Aachen, Germany, are doing. They use plants to produce biopharmaceuticals. Those are proteins that, unlike many other medications, cannot be chemically produced.

Biologically produced medications, such as recombinant insulin or therapeutic antibodies to fight cancer, have become indispensable. Plants are particularly suitable for producing complex active substances. The reason is that these substances can be produced inexpensively and on a large scale in plants. Compared to producing them in animal cells, plants have the advantage that they grow quickly, are easy to look after and can be protected well against damaging influences.

Precisely controlled raising of plants

Tobacco was the plant of choice. Dr. Jrgen Drossard explains the reason: Tobacco has long been a very interesting plant for molecular biologists. It is easy to modify, meaning a foreign gene coding for the pharmaceutical protein can be introduced. In addition, a lot of biomass grows quickly and therefore a greater quantity of the desired proteins is also produced. The active substances must be absolutely safe. It is for this reason that the requirements both for growing the plants and for the processes and equipment for the preparations are particularly high. The researchers from Aachen passed the stringent tests of the supervisory and approval authorities for both. The tobacco plants are protected from all external influences and grown under precisely controlled conditions. We practically grow them on sterile substrates. And fertilization with manure is absolutely out of the question, of course, says Dr. Thomas Rademacher.

But growing the plants only solved a part of the problem. Because, how does one get as much protein as possible from the leaves that are harvested? The team developed the equipment that is suitable for that itself, because current processes, coming from food technology, for example, work on an entirely different scale. The complete pulping process now takes place in a closed loop.

Biopharmaceuticals for clinical studies

Dr. Jrgen Drossard, Dr. Thomas Rademacher and Dr. Stefan Schillberg from the IME, in cooperation with Prof. Dr. Wiltrud Treffenfeldt from Dow AgroSciences and Dr. ctive substances in transgenic plants and plant suspension cells economically and safely. They are being honored with the Prize for Human-Centered Technology for their achievements.

We wanted to show that it can be done, that biopharmaceuticals can be produced that are suitable for clinical studies, says Dr. Stefan Schillberg of the IME. And this is exactly where the team is at with its development. The proteins that are produced in this manner are currently being tested with the objective that they be used in clinical studies. For example, the antibodies could be used to manufacture a vaginal gel with which women could protect themselves from an HIV infection. In a new project, the researchers are currently working on producing a malaria vaccine in plants.


'/>"/>

Contact: Dr. Stefan Schillberg
stefan.schillberg@ime.fraunhofer.de
49-241-608-511-050
Fraunhofer-Gesellschaft
Source:Eurekalert  

Related biology news :

1. Accelerated lab evolution of biomolecules could yield new generation of medicines
2. Sunlight can influence the breakdown of medicines in the body
3. New treaty on search for life-saving medicines in remote areas
4. 40-year-old test procedure finds modern niche in developing new medicines
5. Reducing gene-damaging impurities in medicines
6. Problem of fake medicines in developing countries could be solved
7. Insight into cells could lead to new approach to medicines
8. Toward bold new anti-cancer medicines
9. Quality of medicines and food ingredients the focus at USP 2009 Annual Scientific Meeting
10. Comprehensive genetic study paves way for new blood-pressure medicines
11. Research exposes the risk to infants from the chemicals used in liquid medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicines from plants
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... announced that the CTNext board of directors has formed a Higher Education Entrepreneurship ... working group composed of institution presidents and other high-ranking representatives from 35 higher ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... Do More ... the transition from being a trusted supplier in the weighing industry, to extending its ... extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for its customers ...
(Date:6/19/2017)... ... ... A colony of healthy honey bees is like a superorganism--individual bees provide ... containing nutrients necessary for growth and survival. Better nutrition gives the colony a strong ... a decline in honey bee health. Sick and weakened bees diminish the colony's resiliency, ...
(Date:6/15/2017)... ... 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer therapeutics ... in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, ... The Series B funding will enable Cybrexa to complete the build-out of its ...
Breaking Biology Technology: